SemperFITrader

$NWBO Great little write up from "MrBobbob" on IHUB Tuesday, October 27, 2026 10:46:56 PM Post# of 847666 The panic from the shorts and bashers is at a frantic level. I’m enjoying this immensely. Tsk effin tsk. Keep it up. You’re making me even more convinced that unconditional approval is imminent. As a reminder, Joanna knows more than all of you combined. You’re guessing.. She knows. Joanna Stanson Why Would She Leave Roswell Park for NWBO Now? Stanson was Director of Dendritic Cell Operations at Roswell Park, one of America’s leading cancer research institutions. She had helped build its GMP manufacturing facility, worked with advanced cell therapies and established herself in a highly specialised field. She had a career, credibility and a position at an established institution. Then, on August 31, 2026, she announced her departure. When asked about her next move, she replied that she was returning to biotechnology to work on a dendritic-cell-based vaccine. On October 26, NWBO announced it had recruited a former Roswell Park Director of DC Operations to strengthen its US manufacturing and regulatory capabilities. Now put yourself in her shoes. NWBO was trading around $0.16. The company was struggling financially, repeatedly raising capital through dilution, and still awaiting an MHRA decision on DCVax-L after almost three years. A rejection could severely damage its finances, its share price and its ability to pursue commercial manufacturing. What would persuade an experienced professional to leave Roswell Park for that uncertainty? A salary? She already had a career. Stock options? At $0.16, with further dilution and potentially devastating consequences from rejection, their future value would depend heavily on the company’s success. The excitement of building something? Certainly. But there needs to be something financially and operationally viable to build. And most importantly, why take that risk before approval when she could simply wait? Stanson is someone who understands dendritic-cell manufacturing from the inside. She has worked in the same scientific environment as Pawel Kalinski, whose next-generation dendritic-cell technology NWBO licensed from Roswell Park and the University of Pittsburgh in 2024. She and Kalinski even appear together on a 2025 scientific abstract involving dendritic-cell immunotherapy. This is someone exceptionally well placed to understand what NWBO has acquired, what it takes to manufacture these treatments and whether its plans are technically credible. I find it entirely plausible that, during recruitment, she was given detailed confidential briefings under appropriate agreements about NWBO’s manufacturing progress, financial plans and future operations. Perhaps she also learned about the NHSBT collaboration before it became public. August 27–28: CHM discusses unresolved concerns concerning an unidentified glioblastoma treatment. August 31: Stanson announces her departure from Roswell Park. October 8: NHS Blood and Transplant publicly announces its DCVax-L manufacturing collaboration, including Leeds and Oxford, with expansion being explored. October 26: NWBO announces its US manufacturing restart plans and specialist recruitment. My belief is that Stanson must have seen something sufficiently convincing to justify a major career decision. I suspect she had far greater confidence in NWBO’s prospects than the share price suggested. And given how much DCVax-L approval matters to the company’s financial future, I believe that confidence likely extended to its regulatory prospects. Of course, we don’t know what she was told, and an employment decision cannot reveal MHRA’s confidential conclusions. Recruitment discussions may also have started before the August CHM meeting. But that doesn’t diminish the central question about her incentives. She could have remained at Roswell Park and waited for the regulatory uncertainty to clear. Instead, she apparently chose to become part of NWBO’s next chapter before the decision. And now we see NHSBT expanding its involvement, NWBO preparing additional US manufacturing capacity and a specialist with direct connections to its licensed dendritic-cell research joining the company. To me, this looks like a professional making an informed decision about where she believes the future lies.

Somebody wants a 1 million @ .1460

$NWBO 1.2 Million buy at 13:05, 13:06 posted. .1669 area.

$NWBO Tale of the Tape today, 7.5 million on volume, up 10.42 percent. For Daily we need to close above .18 and on Weekly we need to do the same. Have not closed above the 20MA on Weekly since May when we were about .30 cents briefly. I will be looking for Volume to pick up if we get closer to a MHRA decision, Thursday OCT 29th is next CHM meeting which we are hoping a decision is made and sometime in November announcement is given.

$NWBO As most heard George Zavoico departure as Vice President of Corporate Development over a week ago comes as we now we see the new PR today by Northwest Bio. I really appreicated all the effort and communication George had put into the company especially spear heading the relationship with the CVC "Cancer Vaccine Coalition" group. He did alot of work unknown to the general public that help build corporate relationships for NWBO. prnewswire.com/news-releases…

$NWBO Seems @StephenMoore addressed @HollensbeAmanda Braelyn this morning on Fox Business. Here is an article in Maui News which looks to be the same content. mauinews.com/opinion/columns… "Every few months, a young 19-year-old woman from South Carolina boards a plane to London. She isn’t going sightseeing. She’s going to get her next dose of a cancer treatment that was invented in the United States, developed by an American company, and credited by her doctors with clearing a brain tumor other surgeons had refused to touch. She was diagnosed with glioblastoma at 16. It is the most common and most lethal brain cancer, the disease that killed John McCain and Beau Biden. Her tumor came back so aggressively after her first surgery that doctors stopped operating. This was a death sentence."

$NWBO Is it possible my well aged special labeled wine finally gets Opened in November 2026 or will the bottle continue to age? She will be opened on first approval and celebrated regardless of where SP lands.